Sequential therapy with inotuzumab ozogamicin, CD19 CAR T cells, and blinatumomab in an elderly patient with relapsed acute lymphoblastic leukemia

Ann Hematol. 2021 Feb;100(2):587-589. doi: 10.1007/s00277-020-04227-8. Epub 2020 Aug 22.

Authors

Ramona Wullenkord¹, Christian Reicherts¹, Jan-Henrik Mikesch¹, Julia Marx¹, Klaus Wethmar¹, Jörn Albring¹, Simon Call¹, Georg Lenz¹, Matthias Stelljes²

Affiliations

¹ Department of Medicine A, Hematology and Oncology, University of Münster, Albert-Schweitzer-Campus 1, 48149, Münster, Germany.
² Department of Medicine A, Hematology and Oncology, University of Münster, Albert-Schweitzer-Campus 1, 48149, Münster, Germany. [email protected].

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Aged
Antibodies, Bispecific / therapeutic use*
Antigens, CD19 / immunology*
Female
Flow Cytometry
Humans
Immunotherapy, Adoptive*
Inotuzumab Ozogamicin / therapeutic use*
Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy*
Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
Recurrence
T-Lymphocytes / immunology*

Substances

Antibodies, Bispecific
Antigens, CD19
CD19 molecule, human
blinatumomab
Inotuzumab Ozogamicin